All In Biotech

Drug Trial Radar · NCT06526338

Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants With Hepatocellular Carcinoma After Complete Radiological Response After Surgical Resection and Local Ablation or Local Ablation Alone

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

315

Planned (sponsor's estimate)

Start

Jul 24, 2024

Primary completion

Dec 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Robert C. MartinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma

Interventions

  • 1.0% IP-001 for injectionDrug

    Participants will receive intratumoral injection of 1.0% IP-001 following local microwave ablation or surgical resection and local microwave ablation

  • Surgical Resection and Local AblationProcedure

    Participants will undergo surgical resection of the tumor and local microwave ablation

  • Local Ablation AloneProcedure

    Participants will have local ablation of the tumor by microwave ablation alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free SurvivalTime frame: From Date of Randomization until date of documented progression, assessed up to 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Louisville

    Louisville, Kentucky · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.